You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Patient stories*
*all profiles are fictional

Patients with severe asthma are already benefiting from Nucala. Despite their severe asthma, Jenna and Gregg feel that they have their lives back.

Go to Top Close

Meet the types of patients who could benefit from Nucala

The following patient profiles are fictional case studies* that have been designed to help you recognise severe eosinophilic asthma.

Before diagnosing patients with severe asthma, you should ensure the patient is adhering to their current asthma medications, and that any co-morbid conditions have been addressed and treated. 1

Click on a patient to get started

*Fictional patient for discussion only.


  1. Nucala SmPC, 2019. Available at Accessed January 2019.
  2. GINA Global Strategy for asthma management and prevention. Available at: Accessed January 2019.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at Adverse events can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Copyright © 2019 GlaxoSmithKline Group of Companies. All rights reserved.
Nucala is a registered trademark of the GlaxoSmithKline Group of Companies.